Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients (EPIC-SR).
Clinical trial NCT05011513 · TERMINATED
Trial details
- NCT number
- NCT05011513
- Sponsor
- Pfizer
- Status
- TERMINATED
- Phase
- Phase 2, Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2021-08-25
- Primary completion
- 2022-07-25
- Enrollment
- 1440
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.